Drugs / JY017
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07201727 | Sep 2025 → May 2028 expected | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JY017 | “For patients with refractory and relapsed AML, CD123+CLL-1 dual-target CAR-T cells (JY017) are used for treatment.” NCT07201727 ↗ |
| Modality | Cell therapy | “CD123+CLL-1 dual-target CAR-T cells” NCT07201727 ↗ |